Spectral AI, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $51.6M
- Price
- $1.62
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.62%
- Volume
- 137.6K
About
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.
Quick stats
Shares outstanding31.8M
Computed float24.7M
Float / shares77.5%
Cash runway (months)7.3
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001833498
Websitehttps://www.spectral-ai.com
AI Summary
AI-generated1/23
majorbullishearnings
Spectral AI Announces 2026 Second Quarter Financial Results
Spectral AI reported Q2 revenue of $3.5 million, a decrease from the prior year driven by the transition to cost-share provisions in its BARDA contract following FDA clearance.
Despite the revenue dip, the company significantly narrowed its net loss to $(0.13) per share and maintained a strong cash position of $14.0 million, supplemented by a $6.5 million draw on its credit facility.
Management reiterated full-year revenue guidance of approximately $18.5 million and confirmed that the DeepView System remains on track for first commercial sales in the U.S. by the end of 2026.
Red flags
- Revenue declined year-over-year from $5.1 million to $3.5 million
- Gross margin contracted to 31.6% from 45.2% due to cost-share provisions